{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:22:27Z","timestamp":1793733747069,"version":"4.6.1"},"reference-count":253,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"crossref","award":["1400-2-22-21687"],"award-info":[{"award-number":["1400-2-22-21687"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"crossref","award":["1400-2-22-21687"],"award-info":[{"award-number":["1400-2-22-21687"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurofibromatosis type 2 (NF2) is a genetic condition marked by the development of multiple benign tumors in the nervous system. The most common tumors associated with NF2 are bilateral vestibular schwannoma, meningioma, and ependymoma. The clinical manifestations of NF2 depend on the site of involvement. Vestibular schwannoma can present with hearing loss, dizziness, and tinnitus, while spinal tumor leads to debilitating pain, muscle weakness, or paresthesias. Clinical diagnosis of NF2 is based on the Manchester criteria, which have been updated in the last decade. NF2 is caused by loss-of-function mutations in the\n                    <jats:italic>NF2<\/jats:italic>\n                    gene on chromosome 22, leading the merlin protein to malfunction. Over half of NF2 patients have de novo mutations, and half of this group are mosaic. NF2 can be managed by surgery, stereotactic radiosurgery, monoclonal antibody bevacizumab, and close observation. However, the nature of multiple tumors and the necessity of multiple surgeries over the lifetime, inoperable tumors like meningiomatosis with infiltration of the sinus or in the area of the lower cranial nerves, the complications caused by the operation, the malignancies induced by radiotherapy, and inefficiency of cytotoxic chemotherapy due to the benign nature of NF-related tumors have led a march toward exploring targeted therapies. Recent advances in genetics and molecular biology have allowed identifying and targeting of underlying pathways in the pathogenesis of NF2. In this review, we explain the clinicopathological characteristics of NF2, its genetic and molecular background, and the current knowledge and challenges of implementing genetics to develop efficient therapies\n                    <jats:italic>.<\/jats:italic>\n                  <\/jats:p>","DOI":"10.1186\/s12935-023-02940-8","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T22:01:17Z","timestamp":1684792877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The genetic landscape and possible therapeutics of neurofibromatosis type 2"],"prefix":"10.1186","volume":"23","author":[{"given":"Mohammad Amin","family":"Ghalavand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimohamad","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Taghizadeh-Hesary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Garshasbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Falah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"11","key":"2940_CR1","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.3390\/ijms22115850","volume":"22","author":"R Tamura","year":"2021","unstructured":"Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. 2021;22(11):5850.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2940_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/ijms22020690","volume":"22","author":"S Bachir","year":"2021","unstructured":"Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, et al. Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. J Int J Mol Sci. 2021;22(2):690.","journal-title":"J Int J Mol Sci"},{"issue":"72","key":"2940_CR3","first-page":"393","volume":"18","author":"J Wishart","year":"1822","unstructured":"Wishart J. Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J. 1822;18(72):393.","journal-title":"Edinburgh Med Surg J"},{"issue":"5","key":"2940_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/00006123-199605000-00004","volume":"38","author":"VF Mautner","year":"1996","unstructured":"Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38(5):880\u20135.","journal-title":"Neurosurgery"},{"key":"2940_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2940_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93\u20137.","journal-title":"Otol Neurotol"},{"issue":"2","key":"2940_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1086\/422700","volume":"75","author":"ME Baser","year":"2004","unstructured":"Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet. 2004;75(2):231\u20139.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"2940_CR8","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/lary.25976","volume":"126","author":"A Picry","year":"2016","unstructured":"Picry A, Bonne NX, Ding J, Aboukais R, Lejeune JP, Baroncini M, et al. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: a volumetric consideration. Laryngoscope. 2016;126(10):2358\u201362.","journal-title":"Laryngoscope"},{"issue":"7","key":"2940_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrneurol.2011.82","volume":"7","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol. 2011;7(7):392\u20139.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"2940_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fern\u00e1ndez-Valle C. Role of Merlin\/NF2 inactivation in tumor biology. J Oncogene. 2016;35(5):537\u201348.","journal-title":"J Oncogene"},{"issue":"9","key":"2940_CR11","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers11091376","volume":"11","author":"I Gugel","year":"2019","unstructured":"Gugel I, Grimm F, Liebsch M, Zipfel J, Teuber C, Kluwe L, et al. Impact of surgery on long-term results of hearing in neurofibromatosis type-2 associated vestibular schwannomas. Cancers. 2019;11(9):1376.","journal-title":"Cancers"},{"issue":"5","key":"2940_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1046\/j.1523-1747.2000.00975.x","volume":"114","author":"L Kluwe","year":"2000","unstructured":"Kluwe L, Friedrich RE, Hagel C, Lindenau M, Mautner VF. Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors. J Invest Dermatol. 2000;114(5):1017\u201321.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2940_CR13","doi-asserted-by":"publisher","first-page":"vdaa153","DOI":"10.1093\/noajnl\/vdaa153","volume":"3","author":"Y Ren","year":"2021","unstructured":"Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma. Neuro-Oncol Adv. 2021;3(1):vdaa153.","journal-title":"Neuro-Oncol Adv"},{"issue":"1","key":"2940_CR14","doi-asserted-by":"publisher","first-page":"vdac005","DOI":"10.1093\/noajnl\/vdac005","volume":"4","author":"G Roman Souza","year":"2022","unstructured":"Roman Souza G, Abdalla A, Mahadevan D. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-Oncol Adv. 2022;4(1):vdac005.","journal-title":"Neuro-Oncol Adv"},{"key":"2940_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/DDDT.S280069","volume":"15","author":"J Long","year":"2021","unstructured":"Long J, Zhang Y, Huang X, Ren J, Zhong P, Wang B. A review of drug therapy in vestibular schwannoma. Drug Des Dev Ther. 2021;15:75\u201385.","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"2940_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","volume":"54","author":"D Halliday","year":"2017","unstructured":"Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, et al. Genetic severity score predicts clinical phenotype in NF2. J Med Genet. 2017;54(10):657\u201364.","journal-title":"J Med Genet"},{"issue":"6429","key":"2940_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363(6429):515\u201321.","journal-title":"Nature"},{"issue":"12","key":"2940_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jmg.29.12.841","volume":"29","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29(12):841\u20136.","journal-title":"J Med Genet"},{"issue":"9","key":"2940_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1101\/gad.1054603","volume":"17","author":"D Lallemand","year":"2003","unstructured":"Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17(9):1090\u2013100.","journal-title":"Genes Dev"},{"issue":"1","key":"2940_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41436-019-0598-7","volume":"22","author":"DG Evans","year":"2020","unstructured":"Evans DG, Hartley CL, Smith PT, King AT, Bowers NL, Tobi S, et al. Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med. 2020;22(1):53\u20139.","journal-title":"Genet Med"},{"issue":"2","key":"2940_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","volume":"77","author":"S Selvanathan","year":"2010","unstructured":"Selvanathan S, Shenton A, Ferner R, Wallace A, Huson S, Ramsden R, et al. Further genotype\u2013phenotype correlations in neurofibromatosis 2. J Clin Genet. 2010;77(2):163\u201370.","journal-title":"J Clin Genet"},{"issue":"3","key":"2940_CR22","first-page":"727","volume":"63","author":"DG Evans","year":"1998","unstructured":"Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998;63(3):727\u201336.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"2940_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/jmg.37.7.542","volume":"37","author":"M Baser","year":"2000","unstructured":"Baser M, Wallace A, Strachan T, Evans D. Clinical and molecular correlates of somatic mosaicism in neurofibromatosis 2. J J Med Genet. 2000;37(7):542\u20133.","journal-title":"J J Med Genet"},{"issue":"7","key":"2940_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/jmg.2006.047753","volume":"44","author":"DG Evans","year":"2007","unstructured":"Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni\/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet. 2007;44(7):424\u20138.","journal-title":"J Med Genet"},{"issue":"5","key":"2940_CR25","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1097\/MAO.0000000000002613","volume":"41","author":"CT Dinh","year":"2020","unstructured":"Dinh CT, Nisenbaum E, Chyou D, Misztal C, Yan D, Mittal R, et al. Genomics, epigenetics, and hearing loss in neurofibromatosis type 2. Otol Neurotol. 2020;41(5):e529.","journal-title":"Otol Neurotol"},{"issue":"7","key":"2940_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/jmedgenet-2020-107548","volume":"59","author":"N Catas\u00fas","year":"2022","unstructured":"Catas\u00fas N, Garc\u00eda B, Galvan I, Plana A, Negro A, Rosas I, et al. Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component. J Med Genet. 2022;59(7):678\u2013686. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107548. Epub 2021 Aug 4.","journal-title":"J Med Genet"},{"issue":"1","key":"2940_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14737175.2018.1399795","volume":"18","author":"J Halliday","year":"2018","unstructured":"Halliday J, Rutherford SA, McCabe MG, Evans DG. An update on the diagnosis and treatment of vestibular schwannoma. Expert Rev Neurother. 2018;18(1):29\u201339.","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"2940_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/jmg.2004.027953","volume":"42","author":"DG Evans","year":"2005","unstructured":"Evans DG, Maher ER, Baser ME. Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. J Med Genet. 2005;42(8):630\u20132.","journal-title":"J Med Genet"},{"issue":"8","key":"2940_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1101\/gad.13.8.978","volume":"13","author":"M Giovannini","year":"1999","unstructured":"Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, van der Valk M, Woodruff JM, Goutebroze L, et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 1999;13(8):978\u201386.","journal-title":"Genes Dev"},{"issue":"13","key":"2940_CR30","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14(13):1617\u201330.","journal-title":"Genes Dev"},{"issue":"5","key":"2940_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/humu.24370","volume":"43","author":"KV Sadler","year":"2022","unstructured":"Sadler KV, Rowlands CF, Smith PT, Hartley CL, Bowers NL, Roberts NY, et al. Re-evaluation of missense variant classifications in NF2. Hum Mutat. 2022;43(5):643\u201354.","journal-title":"Hum Mutat"},{"issue":"4","key":"2940_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmg.2010.085241","volume":"48","author":"MJ Smith","year":"2011","unstructured":"Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet. 2011;48(4):261\u20135.","journal-title":"J Med Genet"},{"issue":"1","key":"2940_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88(1):87\u201392.","journal-title":"Neurology"},{"issue":"16","key":"2940_CR34","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","volume":"588","author":"J Cooper","year":"2014","unstructured":"Cooper J, Giancotti FG. Molecular insights into NF2\/Merlin tumor suppressor function. FEBS Lett. 2014;588(16):2743\u201352.","journal-title":"FEBS Lett"},{"issue":"1","key":"2940_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/WNO.0000000000000675","volume":"39","author":"SL Painter","year":"2019","unstructured":"Painter SL, Sipkova Z, Emmanouil B, Halliday D, Parry A, Elston JS. Neurofibromatosis type 2-related eye disease correlated with genetic severity type. J Neuroophthalmol. 2019;39(1):44\u20139.","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"2940_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41576-020-00300-0","volume":"22","author":"B Carter","year":"2021","unstructured":"Carter B, Zhao K. The epigenetic basis of cellular heterogeneity. Nat Rev Genet. 2021;22(4):235\u201350.","journal-title":"Nat Rev Genet"},{"issue":"7271","key":"2940_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature08514","volume":"462","author":"R Lister","year":"2009","unstructured":"Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315\u201322.","journal-title":"Nature"},{"issue":"4","key":"2940_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/(SICI)1096-8628(19960906)64:4<563::AID-AJMG7>3.0.CO;2-Q","volume":"64","author":"ME Baser","year":"1996","unstructured":"Baser ME, Ragge NK, Riccardi VM, Janus T, Gantz B, Pulst SM. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet. 1996;64(4):563\u20137.","journal-title":"Am J Med Genet"},{"issue":"4","key":"2940_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1067\/mhn.2000.107683","volume":"123","author":"DB Welling","year":"2000","unstructured":"Welling DB, Akhmametyeva EM, Daniels RL, Lasak JM, Zhu L, Miles-Markley BA, et al. Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngol Head Neck Surg. 2000;123(4):413\u20138.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"2940_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2443.2001.00432.x","volume":"6","author":"T Kino","year":"2001","unstructured":"Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, et al. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes cells. 2001;6(5):441\u201354.","journal-title":"Genes cells"},{"issue":"15","key":"2940_CR41","first-page":"5601","volume":"9","author":"P Gonzalez-Gomez","year":"2003","unstructured":"Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, Campos JM, et al. CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(15):5601\u20136.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"2940_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000334968","volume":"74","author":"D Koutsimpelas","year":"2012","unstructured":"Koutsimpelas D, Ruerup G, Mann WJ, Brieger J. Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas. ORL J Oto-Rhino-Laryngol Relat Spec. 2012;74(1):33\u20137.","journal-title":"ORL J Oto-Rhino-Laryngol Relat Spec"},{"issue":"6","key":"2940_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2990.2010.01090.x","volume":"36","author":"PJ Kullar","year":"2010","unstructured":"Kullar PJ, Pearson DM, Malley DS, Collins VP, Ichimura K. CpG island hypermethylation of the neurofibromatosis type 2 (NF2) gene is rare in sporadic vestibular schwannomas. Neuropathol Appl Neurobiol. 2010;36(6):505\u201314.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"2940_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cancergencyto.2006.02.022","volume":"172","author":"MJ Bello","year":"2007","unstructured":"Bello MJ, Martinez-Glez V, Franco-Hernandez C, Pefla-Granero C, de Campos JM, Isla A, et al. DNA methylation pattern in 16 tumor-related genes in schwannomas. Cancer Genet Cytogenet. 2007;172(1):84\u20136.","journal-title":"Cancer Genet Cytogenet"},{"issue":"8","key":"2940_CR45","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/01.mao.0000226291.42165.22","volume":"27","author":"L Lassaletta","year":"2006","unstructured":"Lassaletta L, Bello MJ, Del R\u00edo L, Alfonso C, Roda JM, Rey JA, et al. DNA methylation of multiple genes in vestibular schwannoma: relationship with clinical and radiological findings. Otol Neurotol. 2006;27(8):1180\u20135.","journal-title":"Otol Neurotol"},{"issue":"7","key":"2940_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1001\/archoto.2009.79","volume":"135","author":"ZK Ahmad","year":"2009","unstructured":"Ahmad ZK, Altuna X, Lopez JP, An Y, Wang-Rodriguez J, Juneja VR, et al. p73 expression and function in vestibular schwannoma. Arch Otolaryngol Head Neck Surg. 2009;135(7):662\u20139.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"9 Supplement","key":"2940_CR47","first-page":"235","volume":"67","author":"J Jelinek","year":"2007","unstructured":"Jelinek J, Gharibyan V, He R, Saraf A, Lau S, Prchal J, Issa JP. DNA methylation of HOX genes in leukemia and myeloproliferative disorders. Cancer Res. 2007;67(9 Supplement):235.","journal-title":"Cancer Res"},{"issue":"1","key":"2940_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2233","volume":"11","author":"S Tommasi","year":"2009","unstructured":"Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res. 2009;11(1):1\u201317.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2940_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/gcc.22232","volume":"54","author":"M Torres-Mart\u00edn","year":"2015","unstructured":"Torres-Mart\u00edn M, Lassaletta L, de Campos JM, Isla A, Pinto GR, Burbano RR, et al. Genome-wide methylation analysis in vestibular schwannomas shows putative mechanisms of gene expression modulation and global hypomethylation at the HOX gene cluster. Genes Chromosom Cancer. 2015;54(4):197\u2013209.","journal-title":"Genes Chromosom Cancer"},{"issue":"1","key":"2940_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/geno.2001.6672","volume":"79","author":"LS Chang","year":"2002","unstructured":"Chang LS, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics. 2002;79(1):63\u201376.","journal-title":"Genomics"},{"issue":"9","key":"2940_CR51","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/MAO.0b013e3181f20655","volume":"31","author":"JA Cioffi","year":"2010","unstructured":"Cioffi JA, Yue WY, Mendolia-Loffredo S, Hansen KR, Wackym PA, Hansen MR. MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival. Otol Neurotol. 2010;31(9):1455\u201362.","journal-title":"Otol Neurotol"},{"issue":"6","key":"2940_CR52","doi-asserted-by":"publisher","first-page":"e65868","DOI":"10.1371\/journal.pone.0065868","volume":"8","author":"M Torres-Martin","year":"2013","unstructured":"Torres-Martin M, Lassaletta L, de Campos JM, Isla A, Gavilan J, Pinto GR, et al. Global profiling in vestibular schwannomas shows critical deregulation of microRNAs and upregulation in those included in chromosomal region 14q32. PLoS ONE. 2013;8(6):e65868.","journal-title":"PLoS ONE"},{"issue":"12","key":"2940_CR53","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.18632\/oncotarget.1422","volume":"4","author":"A Petrilli","year":"2013","unstructured":"Petrilli A, Bott M, Fern\u00e1ndez-Valle C. Inhibition of SIRT2 in merlin\/NF2-mutant Schwann cells triggers necrosis. Oncotarget. 2013;4(12):2354\u201365.","journal-title":"Oncotarget"},{"issue":"5","key":"2940_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DT, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682\u201394.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2940_CR55","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1148\/radiology.218.2.r01fe40434","volume":"218","author":"NJ Patronas","year":"2001","unstructured":"Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. 2001;218(2):434\u201342.","journal-title":"Radiology"},{"issue":"5","key":"2940_CR56","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3171\/spi.2005.2.5.0574","volume":"2","author":"G Dow","year":"2005","unstructured":"Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A. Spinal tumors in neurofibromatosis type 2 Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine. 2005;2(5):574\u20139.","journal-title":"J Neurosurg Spine"},{"key":"2940_CR57","first-page":"1993","volume-title":"GeneReviews Seattle (WA): University of Washington, Seattle Copyright \u00a9 University of Washington Seattle. Gene Reviews is a registered trademark of the all rights reserved","author":"DG Evans","year":"1993","unstructured":"Evans DG, et al. Neurofibromatosis 2. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews Seattle (WA): University of Washington, Seattle Copyright \u00a9 University of Washington Seattle. Gene Reviews is a registered trademark of the all rights reserved. Seattle: University of Washington; 1993. p. 1993\u20132022."},{"issue":"10","key":"2940_CR58","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1212\/WNL.0000000000008065","volume":"93","author":"C Gaudioso","year":"2019","unstructured":"Gaudioso C, Listernick R, Fisher MJ, Campen CJ, Paz A, Gutmann DH. Neurofibromatosis 2 in children presenting during the first decade of life. Neurology. 2019;93(10):e964\u20137.","journal-title":"Neurology"},{"issue":"1","key":"2940_CR59","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13023-022-02379-6","volume":"17","author":"S Legoupil","year":"2022","unstructured":"Legoupil S, Bessis D, Picard F, Mallet S, Mazereeuw J, Phan A, et al. Dermatologic manifestations in paediatric neurofibromatosis type 2: a cross sectional descriptive multicentric study. Orphanet J Rare Dis. 2022;17(1):242.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2940_CR60","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1212\/WNL.0000000000007898","volume":"93","author":"T Godel","year":"2019","unstructured":"Godel T, B\u00e4umer P, Farschtschi S, Gugel I, Kronlage M, Hofstadler B, et al. Peripheral nervous system alterations in infant and adult neurofibromatosis type 2. Neurology. 2019;93(6):e590\u20138.","journal-title":"Neurology"},{"issue":"6","key":"2940_CR61","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/adc.81.6.496","volume":"81","author":"DG Evans","year":"1999","unstructured":"Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81(6):496\u20139.","journal-title":"Arch Dis Child"},{"issue":"Pt 5","key":"2940_CR62","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/brain\/awf115","volume":"125","author":"AD Sperfeld","year":"2002","unstructured":"Sperfeld AD, Hein C, Schr\u00f6der JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain J Neurol. 2002;125(Pt 5):996\u20131004.","journal-title":"Brain J Neurol"},{"key":"2940_CR63","doi-asserted-by":"publisher","first-page":"687201","DOI":"10.3389\/fonc.2021.687201","volume":"11","author":"J Gan","year":"2021","unstructured":"Gan J, Zhang Y, Wu J, Lei D, Zhang F, Zhao H, et al. Current understanding of hearing loss in sporadic vestibular schwannomas: a systematic review. Front Oncol. 2021;11:687201.","journal-title":"Front Oncol"},{"issue":"19","key":"2940_CR64","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1101\/gad.1335605","volume":"19","author":"AI McClatchey","year":"2005","unstructured":"McClatchey AI, Giovannini M. Membrane organization and tumorigenesis\u2013the NF2 tumor suppressor. Merlin Genes Dev. 2005;19(19):2265\u201377.","journal-title":"Merlin Genes Dev"},{"issue":"Suppl","key":"2940_CR65","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0385-8146(01)00078-5","volume":"28","author":"T Sakamoto","year":"2001","unstructured":"Sakamoto T, Fukuda S, Inuyama Y. Hearing loss and growth rate of acoustic neuromas in follow-up observation policy. Auris Nasus Larynx. 2001;28(Suppl):S23\u20137.","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"2940_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000096152","volume":"12","author":"P Caye-Thomasen","year":"2007","unstructured":"Caye-Thomasen P, Dethloff T, Hansen S, Stangerup SE, Thomsen J. Hearing in patients with intracanalicular vestibular schwannomas. Audiol Neurootol. 2007;12(1):1\u201312.","journal-title":"Audiol Neurootol"},{"issue":"5","key":"2940_CR67","first-page":"644","volume":"19","author":"J Kanzaki","year":"1998","unstructured":"Kanzaki J, Ogawa K, Inoue Y, Shiobara R, Toya S. Quality of hearing preservation in acoustic neuroma surgery. Am J Otol. 1998;19(5):644\u20138.","journal-title":"Am J Otol"},{"issue":"2","key":"2940_CR68","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3171\/2010.5.JNS10256","volume":"114","author":"ME Sughrue","year":"2011","unstructured":"Sughrue ME, Kaur R, Kane AJ, Rutkowski MJ, Yang I, Pitts LH, et al. Intratumoral hemorrhage and fibrosis in vestibular schwannoma: a possible mechanism for hearing loss. J Neurosurg. 2011;114(2):386\u201393.","journal-title":"J Neurosurg"},{"issue":"5","key":"2940_CR69","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/00129492-200109000-00024","volume":"22","author":"B Badie","year":"2001","unstructured":"Badie B, Pyle GM, Nguyen PH, Hadar EJ. Elevation of internal auditory canal pressure by vestibular schwannomas. Otol Neurotol. 2001;22(5):696\u2013700.","journal-title":"Otol Neurotol"},{"key":"2940_CR70","doi-asserted-by":"publisher","first-page":"18599","DOI":"10.1038\/srep18599","volume":"5","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Landegger LD, Soares VY, Deschler DG, Stankovic KM. Secreted factors from human vestibular schwannomas can cause cochlear damage. Sci Rep. 2015;5:18599.","journal-title":"Sci Rep"},{"issue":"11","key":"2940_CR71","first-page":"1498","volume":"18","author":"VY Soares","year":"2016","unstructured":"Soares VY, Atai NA, Fujita T, Dilwali S, Sivaraman S, Landegger LD, et al. Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells. Neuro Oncol. 2016;18(11):1498\u2013507.","journal-title":"Neuro Oncol"},{"key":"2940_CR72","doi-asserted-by":"publisher","unstructured":"Neurofibromatosis. Conference statement. National institutes of health consensus development conference. Arch Neurol. 1988;45(5):575\u20138. https:\/\/doi.org\/10.1001\/archneur.1988.00520290115023","DOI":"10.1001\/archneur.1988.00520290115023"},{"issue":"304","key":"2940_CR73","first-page":"603","volume":"84","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603\u201318.","journal-title":"Q J Med"},{"issue":"5","key":"2940_CR74","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/archdischild-2017-313154","volume":"103","author":"G Anand","year":"2018","unstructured":"Anand G, Vasallo G, Spanou M, Thomas S, Pike M, Kariyawasam DS, et al. Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Arch Dis Child. 2018;103(5):463\u20139.","journal-title":"Arch Dis Child"},{"issue":"7","key":"2940_CR75","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41436-018-0384-y","volume":"21","author":"DG Evans","year":"2019","unstructured":"Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, et al. Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. 2019;21(7):1525\u201333.","journal-title":"Genet Med"},{"key":"2940_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.05.007","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med. 2022. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007.","journal-title":"Genet Med"},{"key":"2940_CR77","unstructured":"Evans DG, Wen PY. NF2-related schwannomatosis (formerly neurofibromatosis type 2). In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (last updated: Oct 28, 2022)"},{"issue":"7","key":"2940_CR78","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/neuonc\/noy009","volume":"20","author":"C Louvrier","year":"2018","unstructured":"Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschk\u00e9 P, Nectoux J, et al. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro Oncol. 2018;20(7):917\u201329.","journal-title":"Neuro Oncol"},{"key":"2940_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/cge.14310","author":"D Halliday","year":"2023","unstructured":"Halliday D, Emmanouil B, Evans DGR. Updated protocol for genetic testing, screening, and clinical management of individuals at risk of NF2-related schwannomatosis. Clin Genet. 2023. https:\/\/doi.org\/10.1111\/cge.14310.","journal-title":"Clin Genet"},{"key":"2940_CR80","unstructured":"National Health Service (NHS). Treatment of Neurofibromatosis type 2. 2023. https:\/\/www.nhs.uk\/conditions\/neurofibromatosis-type-2\/treatment\/."},{"issue":"2","key":"2940_CR81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","volume":"144","author":"VM Lu","year":"2019","unstructured":"Lu VM, Ravindran K, Graffeo CS, Perry A, Van Gompel JJ, Daniels DJ, et al. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes. J Neurooncol. 2019;144(2):239\u201348.","journal-title":"J Neurooncol"},{"issue":"1","key":"2940_CR82","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijrobp.2008.03.073","volume":"73","author":"S Wentworth","year":"2009","unstructured":"Wentworth S, Pinn M, Bourland JD, Deguzman AF, Ekstrand K, Ellis TL, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009;73(1):208\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15 Suppl","key":"2940_CR83","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/jco.2015.33.15_suppl.2055","volume":"33","author":"SA Grimm","year":"2015","unstructured":"Grimm SA, Kumthekar P, Chamberlain MC, Schiff D, Wen PY, Iwamoto FM, et al. Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. J Clin Oncol. 2015;33(15 Suppl):2055.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2940_CR84","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11060-017-2690-7","volume":"136","author":"M Kalamarides","year":"2018","unstructured":"Kalamarides M, Essayed W, Lejeune JP, Aboukais R, Sterkers O, Bernardeschi D, et al. Spinal ependymomas in NF2: a surgical disease? J Neurooncol. 2018;136(3):605\u201311.","journal-title":"J Neurooncol"},{"issue":"6","key":"2940_CR85","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ane.12490","volume":"133","author":"S Farschtschi","year":"2016","unstructured":"Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, et al. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016;133(6):475\u201380.","journal-title":"Acta Neurol Scand"},{"key":"2940_CR86","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jocn.2021.01.010","volume":"86","author":"MH Snyder","year":"2021","unstructured":"Snyder MH, Ampie L, DiDomenico JD, Asthagiri AR. Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: systematic review and case. J Clin Neurosci. 2021;86:79\u201384.","journal-title":"J Clin Neurosci"},{"issue":"4","key":"2940_CR87","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/MAO.0000000000002994","volume":"42","author":"NL Deep","year":"2021","unstructured":"Deep NL, Patel EJ, Shapiro WH, Waltzman SB, Jethanamest D, McMenomey SO, et al. Cochlear implant outcomes in neurofibromatosis type 2: implications for management. Otol Neurotol. 2021;42(4):540\u20138.","journal-title":"Otol Neurotol"},{"issue":"6","key":"2940_CR88","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/MLG.0b013e31804b1ae7","volume":"117","author":"BA Neff","year":"2007","unstructured":"Neff BA, Wiet RM, Lasak JM, Cohen NL, Pillsbury HC, Ramsden RT, et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope. 2007;117(6):1069\u201372.","journal-title":"Laryngoscope"},{"issue":"4","key":"2940_CR89","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmg.2005.036319","volume":"43","author":"DG Evans","year":"2006","unstructured":"Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43(4):289\u201394.","journal-title":"J Med Genet"},{"issue":"4","key":"2940_CR90","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/neuonc\/nou317","volume":"17","author":"R Dewan","year":"2015","unstructured":"Dewan R, Pemov A, Kim HJ, Morgan KL, Vasquez RA, Chittiboina P, et al. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol. 2015;17(4):566\u201373.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2940_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"DG Evans","year":"2005","unstructured":"Evans DG, Baser ME, O\u2019Reilly B, Rowe J, Gleeson M, Saeed S, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19(1):5\u201312.","journal-title":"Br J Neurosurg"},{"key":"2940_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.wneu.2017.08.159","volume":"109","author":"LK Chung","year":"2018","unstructured":"Chung LK, Nguyen TP, Sheppard JP, Lagman C, Tenn S, Lee P, et al. A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas. World Neurosurg. 2018;109:47\u201358.","journal-title":"World Neurosurg"},{"issue":"9","key":"2940_CR93","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/jnnp.74.9.1288","volume":"74","author":"JG Rowe","year":"2003","unstructured":"Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74(9):1288\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"23","key":"2940_CR94","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.3390\/cancers13236032","volume":"13","author":"LD Sanchez","year":"2021","unstructured":"Sanchez LD, Bui A, Klesse LJ. Targeted therapies for the neurofibromatoses. Cancers. 2021;13(23):6032.","journal-title":"Cancers"},{"issue":"1","key":"2940_CR95","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","volume":"117","author":"MS Dirks","year":"2012","unstructured":"Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, et al. Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109\u201317.","journal-title":"J Neurosurg"},{"issue":"5","key":"2940_CR96","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72(5):791\u2013800.","journal-title":"Cell"},{"issue":"4","key":"2940_CR97","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus. J Cell. 2010;140(4):477\u201390.","journal-title":"J Cell"},{"issue":"5","key":"2940_CR98","first-page":"471","volume":"6","author":"AM Petrilli","year":"2014","unstructured":"Petrilli AM, Fuse MA, Donnan MS, Bott M, Sparrow NA, Tondera D, et al. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. Am J Trans Res. 2014;6(5):471\u201393.","journal-title":"Am J Trans Res"},{"issue":"4","key":"2940_CR99","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.bbrc.2005.12.122","volume":"340","author":"JY Lim","year":"2006","unstructured":"Lim JY, Kim H, Jeun SS, Kang SG, Lee KJ. Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun. 2006;340(4):1151\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2940_CR100","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/cdd.2016.54","volume":"23","author":"M Kim","year":"2016","unstructured":"Kim M, Kim S, Lee S, Kim W, Sohn M, Kim H, et al. Merlin inhibits Wnt\/\u03b2-catenin signaling by blocking LRP6 phosphorylation. J Cell Death Differ. 2016;23(10):1638\u201347.","journal-title":"J Cell Death Differ"},{"issue":"15","key":"2940_CR101","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al. NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29(15):4250\u201361.","journal-title":"Mol Cell Biol"},{"key":"2940_CR102","doi-asserted-by":"publisher","first-page":"731441","DOI":"10.3389\/fonc.2021.731441","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Long J, Ren J, Huang X, Zhong P, Wang B. Potential molecular biomarkers of vestibular schwannoma growth: progress and prospects. Front Oncol. 2021;11:731441.","journal-title":"Front Oncol"},{"issue":"8","key":"2940_CR103","doi-asserted-by":"publisher","first-page":"e0129151","DOI":"10.1371\/journal.pone.0129151","volume":"10","author":"A Zoch","year":"2015","unstructured":"Zoch A, Mayerl S, Schulz A, Greither T, Frappart L, R\u00fcbsam J, et al. Merlin isoforms 1 and 2 both act as tumour suppressors and are required for optimal sperm maturation. PLoS ONE. 2015;10(8):e0129151.","journal-title":"PLoS ONE"},{"issue":"3","key":"2940_CR104","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12253-013-9644-y","volume":"19","author":"N Pe\u0107ina-\u0160laus","year":"2013","unstructured":"Pe\u0107ina-\u0160laus N. Merlin, the NF2 gene product. Pathol Oncol Res. 2013;19(3):365\u201373.","journal-title":"Pathol Oncol Res"},{"issue":"1\u20132","key":"2940_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4838(98)00103-4","volume":"1387","author":"O Turunen","year":"1998","unstructured":"Turunen O, Sainio M, J\u00e4\u00e4skel\u00e4inen J, Carp\u00e9n O, Vaheri A. Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein. Biochim Biophys Acta. 1998;1387(1\u20132):1\u201316.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2940_CR106","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jmb.2006.10.075","volume":"365","author":"Q Li","year":"2007","unstructured":"Li Q, Nance MR, Kulikauskas R, Nyberg K, Fehon R, Karplus PA, et al. Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain. J Mol Biol. 2007;365(5):1446\u201359.","journal-title":"J Mol Biol"},{"issue":"8","key":"2940_CR107","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1091\/mbc.6.8.1061","volume":"6","author":"R Gary","year":"1995","unstructured":"Gary R, Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell. 1995;6(8):1061\u201375.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"2940_CR108","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2009.02.006","volume":"19","author":"AI McClatchey","year":"2009","unstructured":"McClatchey AI, Fehon RG. Merlin and the ERM proteins\u2013regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 2009;19(5):198\u2013206.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"2940_CR109","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7","volume":"51","author":"HM Xu","year":"1998","unstructured":"Xu HM, Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res. 1998;51(3):403\u201315.","journal-title":"J Neurosci Res"},{"issue":"8","key":"2940_CR110","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.189601","volume":"15","author":"H Morrison","year":"2001","unstructured":"Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001;15(8):968\u201380.","journal-title":"Genes Dev"},{"issue":"8","key":"2940_CR111","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nrm882","volume":"3","author":"A Bretscher","year":"2002","unstructured":"Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3(8):586\u201399.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2940_CR112","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.1074\/jbc.M006708200","volume":"276","author":"R Nguyen","year":"2001","unstructured":"Nguyen R, Reczek D, Bretscher A. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem. 2001;276(10):7621\u20139.","journal-title":"J Biol Chem"},{"issue":"3","key":"2940_CR113","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0092-8674(00)80836-3","volume":"101","author":"MA Pearson","year":"2000","unstructured":"Pearson MA, Reczek D, Bretscher A, Karplus PA. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 2000;101(3):259\u201370.","journal-title":"Cell"},{"issue":"1","key":"2940_CR114","first-page":"32","volume":"1785","author":"DR Scoles","year":"2008","unstructured":"Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta. 2008;1785(1):32\u201354.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"2940_CR115","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/pro.751","volume":"20","author":"SD Yogesha","year":"2011","unstructured":"Yogesha SD, Sharff AJ, Giovannini M, Bricogne G, Izard T. Unfurling of the band 41, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci. 2011;20(12):2113\u201320.","journal-title":"Protein Sci"},{"issue":"5","key":"2940_CR116","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1083\/jcb.200307032","volume":"164","author":"BT Fievet","year":"2004","unstructured":"Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, et al. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol. 2004;164(5):653\u20139.","journal-title":"J Cell Biol"},{"issue":"43","key":"2940_CR117","doi-asserted-by":"publisher","first-page":"29602","DOI":"10.1074\/jbc.M803606200","volume":"283","author":"T Mori","year":"2008","unstructured":"Mori T, Kitano K, Terawaki S, Maesaki R, Fukami Y, Hakoshima T. Structural basis for CD44 recognition by ERM proteins. J Biol Chem. 2008;283(43):29602\u201312.","journal-title":"J Biol Chem"},{"issue":"3","key":"2940_CR118","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/emboj\/cdg039","volume":"22","author":"K Hamada","year":"2003","unstructured":"Hamada K, Shimizu T, Yonemura S, Tsukita S, Tsukita S, Hakoshima T. Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. Embo j. 2003;22(3):502\u201314.","journal-title":"Embo j"},{"issue":"3","key":"2940_CR119","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jmb.2008.05.085","volume":"381","author":"Y Takai","year":"2008","unstructured":"Takai Y, Kitano K, Terawaki S, Maesaki R, Hakoshima T. Structural basis of the cytoplasmic tail of adhesion molecule CD43 and its binding to ERM proteins. J Mol Biol. 2008;381(3):634\u201344.","journal-title":"J Mol Biol"},{"issue":"10","key":"2940_CR120","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/ncb1641","volume":"9","author":"X Tang","year":"2007","unstructured":"Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol. 2007;9(10):1199\u2013207.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2940_CR121","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4161\/cam.1.4.5192","volume":"1","author":"K Ye","year":"2007","unstructured":"Ye K. Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr. 2007;1(4):196\u20138.","journal-title":"Cell Adh Migr"},{"issue":"23","key":"2940_CR122","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1038\/sj.onc.1210988","volume":"27","author":"M Laulajainen","year":"2008","unstructured":"Laulajainen M, Muranen T, Carp\u00e9n O, Gr\u00f6nholm M. Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene. 2008;27(23):3233\u201343.","journal-title":"Oncogene"},{"issue":"2","key":"2940_CR123","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/sj.onc.1207142","volume":"23","author":"EI Surace","year":"2004","unstructured":"Surace EI, Haipek CA, Gutmann DH. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene. 2004;23(2):580\u20137.","journal-title":"Oncogene"},{"issue":"18","key":"2940_CR124","doi-asserted-by":"publisher","first-page":"18559","DOI":"10.1074\/jbc.M313916200","volume":"279","author":"K Alfthan","year":"2004","unstructured":"Alfthan K, Heiska L, Gr\u00f6nholm M, Renkema GH, Carp\u00e9n O. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem. 2004;279(18):18559\u201366.","journal-title":"J Biol Chem"},{"issue":"7102","key":"2940_CR125","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature04856","volume":"442","author":"H Jin","year":"2006","unstructured":"Jin H, Sperka T, Herrlich P, Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature. 2006;442(7102):576\u20139.","journal-title":"Nature"},{"issue":"7","key":"2940_CR126","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1593\/neo.11356","volume":"13","author":"M Laulajainen","year":"2011","unstructured":"Laulajainen M, Muranen T, Nyman TA, Carp\u00e9n O, Gr\u00f6nholm M. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin. Neoplasia. 2011;13(7):643\u201352.","journal-title":"Neoplasia"},{"issue":"1","key":"2940_CR127","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58.","journal-title":"Mol Cancer"},{"issue":"6","key":"2940_CR128","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/sj.onc.1209849","volume":"26","author":"Y Bai","year":"2007","unstructured":"Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene. 2007;26(6):836\u201350.","journal-title":"Oncogene"},{"issue":"8","key":"2940_CR129","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, et al. ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010;12(8):834\u201343.","journal-title":"Neuro Oncol"},{"issue":"12","key":"2940_CR130","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","volume":"69","author":"J Mukherjee","year":"2009","unstructured":"Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, et al. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res. 2009;69(12):5099\u2013107.","journal-title":"Cancer Res"},{"issue":"6","key":"2940_CR131","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3171\/2014.6.JNS131433","volume":"121","author":"S Agnihotri","year":"2014","unstructured":"Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack SC, et al. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. J J Neurosurg. 2014;121(6):1434\u201345.","journal-title":"J J Neurosurg"},{"issue":"1","key":"2940_CR132","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/mao.0b013e31816021f7","volume":"29","author":"A Jacob","year":"2008","unstructured":"Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang L-S. Phosphatidylinositol 3-kinase\/AKT pathway activation in human vestibular schwannoma. J Otol Neurotol. 2008;29(1):58\u201368.","journal-title":"J Otol Neurotol"},{"issue":"52","key":"2940_CR133","doi-asserted-by":"publisher","first-page":"18200","DOI":"10.1073\/pnas.0405971102","volume":"101","author":"R Rong","year":"2004","unstructured":"Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA. 2004;101(52):18200\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2940_CR134","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1128\/MCB.01578-08","volume":"29","author":"MA L\u00f3pez-Lago","year":"2009","unstructured":"L\u00f3pez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol. 2009;29(15):4235\u201349.","journal-title":"Mol Cell Biol"},{"key":"2940_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111633","author":"S Lee","year":"2019","unstructured":"Lee S, Karas PJ, Hadley CC, Bayley VJ, Khan AB, Jalali A, et al. The role of merlin\/NF2 loss in meningioma biology. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111633.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2940_CR136","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"Piccolo S, Dupont S, Cordenonsi M. The biology of YAP\/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287\u2013312.","journal-title":"Physiol Rev"},{"issue":"9","key":"2940_CR137","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/neuonc\/nou020","volume":"16","author":"A Boin","year":"2014","unstructured":"Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. J Neuro Oncol. 2014;16(9):1196\u2013209.","journal-title":"J Neuro Oncol"},{"issue":"1","key":"2940_CR138","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","volume":"26","author":"W Li","year":"2014","unstructured":"Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, et al. Merlin\/NF2 loss-driven tumorigenesis linked to CRL4DCAF1-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus. J Cancer cell. 2014;26(1):48\u201360.","journal-title":"J Cancer cell"},{"issue":"12","key":"2940_CR139","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1593\/neo.111060","volume":"13","author":"L Zhou","year":"2011","unstructured":"Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt\/\u03b2-catenin signaling linked to the PDGFR\/Src and Rac\/PAK pathways. J Neoplasia. 2011;13(12):1101-IN2.","journal-title":"J Neoplasia"},{"issue":"14","key":"2940_CR140","doi-asserted-by":"publisher","first-page":"17991","DOI":"10.18632\/oncotarget.7494","volume":"7","author":"KA Morrow","year":"2016","unstructured":"Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, et al. Loss of tumor suppressor Merlin results in aberrant activation of Wnt\/\u03b2-catenin signaling in cancer. J Oncotarget. 2016;7(14):17991.","journal-title":"J Oncotarget"},{"issue":"17","key":"2940_CR141","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/onc.2010.20","volume":"29","author":"EE Bosco","year":"2010","unstructured":"Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. J Oncogene. 2010;29(17):2540\u20139.","journal-title":"J Oncogene"},{"issue":"12","key":"2940_CR142","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.celrep.2016.02.075","volume":"14","author":"H Hikasa","year":"2016","unstructured":"Hikasa H, Sekido Y, Suzuki A. Merlin\/NF2-Lin28B-let-7 is a tumor-suppressive pathway that is cell-density dependent and hippo independent. J Cell reports. 2016;14(12):2950\u201361.","journal-title":"J Cell reports"},{"issue":"5","key":"2940_CR143","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MOO.0b013e328357d2ee","volume":"20","author":"J Blakeley","year":"2012","unstructured":"Blakeley J. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma. Curr Opin Otolaryngol Head Neck Surg. 2012;20(5):372\u20139.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2940_CR144","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31.","journal-title":"Cell Biosci"},{"issue":"4","key":"2940_CR145","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/neuonc\/not242","volume":"16","author":"M Giovannini","year":"2014","unstructured":"Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, et al. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol. 2014;16(4):493\u2013504.","journal-title":"Neuro Oncol"},{"issue":"2","key":"2940_CR146","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","volume":"133","author":"S Goutagny","year":"2017","unstructured":"Goutagny S, Giovannini M, Kalamarides M. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J Neurooncol. 2017;133(2):443\u20135.","journal-title":"J Neurooncol"},{"issue":"2","key":"2940_CR147","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol. 2015;122(2):313\u201320.","journal-title":"J Neurooncol"},{"issue":"9","key":"2940_CR148","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.ejca.2009.03.013","volume":"45","author":"TX Lee","year":"2009","unstructured":"Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer. 2009;45(9):1709\u201320.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2940_CR149","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/neuonc\/nor072","volume":"13","author":"ML Bush","year":"2011","unstructured":"Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol. 2011;13(9):983\u201399.","journal-title":"Neuro Oncol"},{"issue":"5","key":"2940_CR150","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/lio2.643","volume":"6","author":"DB Welling","year":"2021","unstructured":"Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, et al. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021;6(5):1008\u201319.","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"5","key":"2940_CR151","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00280-020-04229-3","volume":"87","author":"KA Collier","year":"2021","unstructured":"Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, et al. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother Pharmacol. 2021;87(5):599\u2013611.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2940_CR152","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","volume":"26","author":"P Cay\u00e9-Thomasen","year":"2005","unstructured":"Cay\u00e9-Thomasen P, Werther K, Nalla A, B\u00f8g-Hansen TC, Nielsen HJ, Stangerup SE, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol. 2005;26(1):98\u2013101.","journal-title":"Otol Neurotol"},{"issue":"9","key":"2940_CR153","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010;70(9):3483\u201393.","journal-title":"Cancer Res"},{"issue":"4","key":"2940_CR154","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358\u201367.","journal-title":"N Engl J Med"},{"issue":"6","key":"2940_CR155","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046\u201352.","journal-title":"Otol Neurotol"},{"issue":"35","key":"2940_CR156","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, et al. Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol. 2019;37(35):3446\u201354.","journal-title":"J Clin Oncol"},{"key":"2940_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121862","author":"I Gugel","year":"2019","unstructured":"Gugel I, Kluwe L, Zipfel J, Teuber C, Tatagiba M, Mautner VF, et al. Minimal effect of bevacizumab treatment on residual vestibular schwannomas after partial resection in young neurofibromatosis type 2 patients. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11121862.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2940_CR158","doi-asserted-by":"publisher","first-page":"e28228","DOI":"10.1002\/pbc.28228","volume":"67","author":"S Renzi","year":"2020","unstructured":"Renzi S, Michaeli O, Salvador H, Alderete D, Ponce NF, Zapotocky M, et al. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer. 2020;67(5):e28228.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2940_CR159","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"73","author":"KM Slusarz","year":"2014","unstructured":"Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014;73(6):1197\u2013204.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2940_CR160","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","volume":"272","author":"S Farschtschi","year":"2015","unstructured":"Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner VF. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. 2015;272(12):3857\u201360.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2940_CR161","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1038\/s41467-019-13640-1","volume":"10","author":"R Tamura","year":"2019","unstructured":"Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, et al. A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun. 2019;10(1):5758.","journal-title":"Nat Commun"},{"issue":"47","key":"2940_CR162","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, et al. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci USA. 2015;112(47):14676\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 3","key":"2940_CR163","doi-asserted-by":"publisher","first-page":"iii419","DOI":"10.1093\/neuonc\/noaa222.612","volume":"22","author":"S Phadnis","year":"2020","unstructured":"Phadnis S, Hagiwara M, Yaffe A, Mitchell C, Nicolaides T, Akshintala S, et al. NFB-08. Phase II study of axitinib in patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2020;22(Suppl 3):iii419.","journal-title":"Neuro Oncol"},{"issue":"14","key":"2940_CR164","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol. 2016;34(14):1669\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2940_CR165","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/15384047.2014.972765","volume":"16","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Roberts D, Stankovic KM. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells. Cancer Biol Ther. 2015;16(1):170\u20135.","journal-title":"Cancer Biol Ther"},{"key":"2940_CR166","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jtbi.2017.11.025","volume":"439","author":"A Konstorum","year":"2018","unstructured":"Konstorum A, Lowengrub JS. Activation of the HGF\/c-Met axis in the tumor microenvironment: a multispecies model. J Theor Biol. 2018;439:86\u201399.","journal-title":"J Theor Biol"},{"issue":"26","key":"2940_CR167","doi-asserted-by":"publisher","first-page":"8458","DOI":"10.3748\/wjg.v20.i26.8458","volume":"20","author":"D Delitto","year":"2014","unstructured":"Delitto D, Vertes-George E, Hughes SJ, Behrns KE, Trevino JG. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol. 2014;20(26):8458\u201370.","journal-title":"World J Gastroenterol"},{"issue":"17","key":"2940_CR168","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1158\/0008-5472.CAN-15-3541","volume":"76","author":"F Xing","year":"2016","unstructured":"Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, et al. Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. 2016;76(17):4970\u201380.","journal-title":"Cancer Res"},{"issue":"9","key":"2940_CR169","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, et al. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci USA. 2018;115(9):E2077\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2940_CR170","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/1535-7163.MCT-17-0417","volume":"16","author":"MA Fuse","year":"2017","unstructured":"Fuse MA, Plati SK, Burns SS, Dinh CT, Bracho O, Yan D, et al. Combination therapy with c-Met and Src inhibitors induces caspase-dependent apoptosis of merlin-deficient schwann cells and suppresses growth of schwannoma cells. Mol Cancer Ther. 2017;16(11):2387\u201398.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2940_CR171","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cub.2005.02.030","volume":"15","author":"DA Lyons","year":"2005","unstructured":"Lyons DA, Pogoda H-M, Voas MG, Woods IG, Diamond B, Nix R, et al. erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafish. Curr Biol. 2005;15(6):513\u201324.","journal-title":"Curr Biol"},{"issue":"5","key":"2940_CR172","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/MAO.0b013e31821f7d88","volume":"32","author":"ZK Ahmad","year":"2011","unstructured":"Ahmad ZK, Brown CM, Cueva RA, Ryan AF, Doherty JK. ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. Otol Neurotol. 2011;32(5):841\u20137.","journal-title":"Otol Neurotol"},{"issue":"9","key":"2940_CR173","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2012;14(9):1163\u201370.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2940_CR174","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","volume":"139","author":"DS Osorio","year":"2018","unstructured":"Osorio DS, Hu J, Mitchell C, Allen JC, Stanek J, Hagiwara M, et al. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol. 2018;139(3):749\u201355.","journal-title":"J Neurooncol"},{"key":"2940_CR175","doi-asserted-by":"publisher","DOI":"10.3171\/2022.9.JNS22699","author":"F Zhao","year":"2022","unstructured":"Zhao F, Li SW, Zhang S, Li P, Zhao C, Zhao XB, et al. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Neurosurg. 2022. https:\/\/doi.org\/10.3171\/2022.9.JNS22699.","journal-title":"J Neurosurg"},{"issue":"6","key":"2940_CR176","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","volume":"29","author":"JJ Clark","year":"2008","unstructured":"Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol. 2008;29(6):846\u201353.","journal-title":"Otol Neurotol"},{"issue":"7","key":"2940_CR177","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG 2nd. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31(7):1135\u201343.","journal-title":"Otol Neurotol"},{"issue":"1","key":"2940_CR178","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MAO.0b013e3182009665","volume":"32","author":"X Altuna","year":"2011","unstructured":"Altuna X, Lopez JP, Yu MA, Arandazi MJ, Harris JP, Wang-Rodriguez J, et al. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma. Otol Neurotol. 2011;32(1):163\u201370.","journal-title":"Otol Neurotol"},{"issue":"4","key":"2940_CR179","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3171\/2012.6.JNS112263","volume":"117","author":"U Yener","year":"2012","unstructured":"Yener U, Avsar T, Akg\u00fcn E, \u015eeker A, Bayri Y, K\u0131l\u0131\u00e7 T. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay. J Neurosurg. 2012;117(4):697\u2013704.","journal-title":"J Neurosurg"},{"issue":"7","key":"2940_CR180","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/neuonc\/nor056","volume":"13","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol. 2011;13(7):759\u201366.","journal-title":"Neuro Oncol"},{"issue":"19","key":"2940_CR181","doi-asserted-by":"publisher","first-page":"31666","DOI":"10.18632\/oncotarget.15912","volume":"8","author":"AM Petrilli","year":"2017","unstructured":"Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR, et al. Ponatinib promotes a G1 cell-cycle arrest of merlin\/NF2-deficient human schwann cells. Oncotarget. 2017;8(19):31666\u201381.","journal-title":"Oncotarget"},{"issue":"1","key":"2940_CR182","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","volume":"10","author":"JE Sagers","year":"2020","unstructured":"Sagers JE, Beauchamp RL, Zhang Y, Vasilijic S, Wu L, DeSouza P, et al. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Sci Rep. 2020;10(1):4211.","journal-title":"Sci Rep"},{"issue":"49","key":"2940_CR183","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1038\/onc.2012.5","volume":"31","author":"T Mizuno","year":"2012","unstructured":"Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene. 2012;31(49):5117\u201322.","journal-title":"Oncogene"},{"issue":"12","key":"2940_CR184","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-15-1144","volume":"76","author":"W Guerrant","year":"2016","unstructured":"Guerrant W, Kota S, Troutman S, Mandati V, Fallahi M, Stemmer-Rachamimov A, et al. YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2\u2013EGFR signaling axis. Can Res. 2016;76(12):3507\u201319.","journal-title":"Can Res"},{"issue":"11","key":"2940_CR185","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1593\/neo.08642","volume":"10","author":"K Striedinger","year":"2008","unstructured":"Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia. 2008;10(11):1204\u201312.","journal-title":"Neoplasia"},{"issue":"12","key":"2940_CR186","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300\u20135.","journal-title":"Genes Dev"},{"issue":"1","key":"2940_CR187","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.1038\/s41598-017-07632-8","volume":"7","author":"A Al-Moujahed","year":"2017","unstructured":"Al-Moujahed A, Brodowska K, Stryjewski TP, Efstathiou NE, Vasilikos I, Cichy J, et al. Verteporfin inhibits growth of human glioma in vitro without light activation. Sci Rep. 2017;7(1):7602.","journal-title":"Sci Rep"},{"issue":"11","key":"2940_CR188","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/jcmm.13182","volume":"21","author":"WQ Zhang","year":"2017","unstructured":"Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL, et al. Targeting YAP in malignant pleural mesothelioma. J Cell Mol Med. 2017;21(11):2663\u201376.","journal-title":"J Cell Mol Med"},{"key":"2940_CR189","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","author":"AW Tolcher","year":"2022","unstructured":"Tolcher AW, Lakhani NJ, McKean M, Lingaraj T, Victor L, Sanchez-Martin M, et al. A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors. Am Soc Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS3168.","journal-title":"Am Soc Clin Oncol"},{"issue":"2","key":"2940_CR190","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","volume":"25","author":"S Jiao","year":"2014","unstructured":"Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166\u201380.","journal-title":"Cancer Cell"},{"issue":"4","key":"2940_CR191","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.tcb.2015.11.004","volume":"26","author":"G Santinon","year":"2016","unstructured":"Santinon G, Pocaterra A, Dupont S. Control of YAP\/TAZ activity by metabolic and nutrient-sensing pathways. Trends Cell Biol. 2016;26(4):289\u201399.","journal-title":"Trends Cell Biol"},{"issue":"4","key":"2940_CR192","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ncb3111","volume":"17","author":"JS Mo","year":"2015","unstructured":"Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol. 2015;17(4):500\u201310.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"2940_CR193","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","volume":"49","author":"SM White","year":"2019","unstructured":"White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, et al. YAP\/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells. Dev Cell. 2019;49(3):425-43.e9.","journal-title":"Dev Cell"},{"issue":"15","key":"2940_CR194","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, et al. FDA approval summary: selumetinib for plexiform neurofibroma. Clin Cancer Res. 2021;27(15):4142\u20136.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2940_CR195","doi-asserted-by":"publisher","first-page":"e0252048","DOI":"10.1371\/journal.pone.0252048","volume":"16","author":"LS Chang","year":"2021","unstructured":"Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, et al. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE. 2021;16(7):e0252048.","journal-title":"PLoS ONE"},{"key":"2940_CR196","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02371","author":"PK Brastianos","year":"2022","unstructured":"Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, et al. Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.21.02371.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2940_CR197","first-page":"023","volume":"2","author":"CJ Hannan","year":"2020","unstructured":"Hannan CJ, Lewis D, O\u2019Leary C, Donofrio CA, Evans DG, Roncaroli F, et al. The inflammatory microenvironment in vestibular schwannoma. Neuro Oncol Adv. 2020;2(1):023.","journal-title":"Neuro Oncol Adv"},{"issue":"2","key":"2940_CR198","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","volume":"34","author":"M de Vries","year":"2013","unstructured":"de Vries M, Briaire-de Bruijn I, Malessy MJ, de Bru\u00efne SF, van der Mey AG, Hogendoorn PC. Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol. 2013;34(2):347\u201352.","journal-title":"Otol Neurotol"},{"issue":"3","key":"2940_CR199","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/neuonc\/noy177","volume":"21","author":"D Lewis","year":"2019","unstructured":"Lewis D, Roncaroli F, Agushi E, Mosses D, Williams R, Li KL, et al. Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro Oncol. 2019;21(3):314\u201325.","journal-title":"Neuro Oncol"},{"issue":"2","key":"2940_CR200","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00401-016-1583-8","volume":"132","author":"A Schulz","year":"2016","unstructured":"Schulz A, B\u00fcttner R, Hagel C, Baader SL, Kluwe L, Salamon J, et al. The importance of nerve microenvironment for schwannoma development. Acta Neuropathol. 2016;132(2):289\u2013307.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2940_CR201","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00428-018-2503-1","volume":"474","author":"WM de Vries","year":"2019","unstructured":"de Vries WM, Briaire-de Bruijn IH, van Benthem PPG, van der Mey AGL, Hogendoorn PCW. M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma. Virchows Archiv. 2019;474(3):375\u201381.","journal-title":"Virchows Archiv"},{"issue":"1","key":"2940_CR202","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","volume":"138","author":"S Wang","year":"2018","unstructured":"Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol. 2018;138(1):183\u201390.","journal-title":"J Neurooncol"},{"issue":"2","key":"2940_CR203","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00432-018-02825-8","volume":"145","author":"Y Wang","year":"2019","unstructured":"Wang Y, Li P, Wang B, Wang S, Liu P. Identification of myeloid-derived suppressor cells that have an immunosuppressive function in NF2 patients. J Cancer Res Clin Oncol. 2019;145(2):523\u201333.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2940_CR204","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3389\/fonc.2019.00503","volume":"9","author":"M Breun","year":"2019","unstructured":"Breun M, Monoranu CM, Kessler AF, Matthies C, L\u00f6hr M, Hagemann C, et al. [(68)Ga]-Pentixafor PET\/CT for CXCR4-mediated imaging of vestibular schwannomas. Front Oncol. 2019;9:503.","journal-title":"Front Oncol"},{"issue":"11","key":"2940_CR205","doi-asserted-by":"publisher","first-page":"9940","DOI":"10.18632\/oncotarget.24119","volume":"9","author":"M Breun","year":"2018","unstructured":"Breun M, Schwerdtfeger A, Martellotta DD, Kessler AF, Perez JM, Monoranu CM, et al. CXCR4: a new player in vestibular schwannoma pathogenesis. Oncotarget. 2018;9(11):9940\u201350.","journal-title":"Oncotarget"},{"issue":"1","key":"2940_CR206","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3892\/mmr.2015.3415","volume":"12","author":"S Taurone","year":"2015","unstructured":"Taurone S, Bianchi E, Attanasio G, Di Gioia C, Ierin\u00f3 R, Carubbi C, et al. Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue. Mol Med Rep. 2015;12(1):737\u201345.","journal-title":"Mol Med Rep"},{"issue":"5","key":"2940_CR207","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0006-291X(02)02077-6","volume":"296","author":"JY Kim","year":"2002","unstructured":"Kim JY, Kim H, Jeun SS, Rha SJ, Kim YH, Ko YJ, et al. Inhibition of NF-kappaB activation by merlin. Biochem Biophys Res Commun. 2002;296(5):1295\u2013302.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2940_CR208","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/onc.2012.587","volume":"33","author":"S Ammoun","year":"2014","unstructured":"Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, et al. Axl\/Gas6\/NF\u03baB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene. 2014;33(3):336\u201346.","journal-title":"Oncogene"},{"issue":"7","key":"2940_CR209","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.molonc.2015.03.009","volume":"9","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Bri\u00ebt MC, Kao SY, Fujita T, Landegger LD, Platt MP, et al. Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth. Mol Oncol. 2015;9(7):1359\u201370.","journal-title":"Mol Oncol"},{"issue":"1","key":"2940_CR210","doi-asserted-by":"publisher","first-page":"17449","DOI":"10.1038\/s41598-018-36016-9","volume":"8","author":"JE Sagers","year":"2018","unstructured":"Sagers JE, Brown AS, Vasilijic S, Lewis RM, Sahin MI, Landegger LD, et al. Publisher correction: computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Sci Rep. 2018;8(1):17449.","journal-title":"Sci Rep"},{"issue":"5","key":"2940_CR211","first-page":"2385","volume":"34","author":"JH Check","year":"2014","unstructured":"Check JH, Wilson C, Cohen R, Sarumi M. Evidence that mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV. Anticancer Res. 2014;34(5):2385\u20138.","journal-title":"Anticancer Res"},{"issue":"2","key":"2940_CR212","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417\u201326.","journal-title":"Mol Cell"},{"issue":"37","key":"2940_CR213","doi-asserted-by":"publisher","first-page":"E7766","DOI":"10.1073\/pnas.1702946114","volume":"114","author":"H Nakanishi","year":"2017","unstructured":"Nakanishi H, Kawashima Y, Kurima K, Chae JJ, Ross AM, Pinto-Patarroyo G, et al. NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. Proc Natl Acad Sci USA. 2017;114(37):E7766\u201375.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2940_CR214","doi-asserted-by":"publisher","first-page":"107770","DOI":"10.1016\/j.heares.2019.07.007","volume":"381","author":"JE Sagers","year":"2019","unstructured":"Sagers JE, Sahin MI, Moon I, Ahmed SG, Stemmer-Rachamimov A, Brenner GJ, et al. NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. Hear Res. 2019;381:107770.","journal-title":"Hear Res"},{"issue":"1","key":"2940_CR215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2014.12.007","volume":"166","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Kao SY, Fujita T, Landegger LD, Stankovic KM. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl Res. 2015;166(1):1\u201311.","journal-title":"Transl Res"},{"issue":"4","key":"2940_CR216","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1227\/NEU.0b013e318208f5c7","volume":"68","author":"B Hong","year":"2011","unstructured":"Hong B, Krusche CA, Schwabe K, Friedrich S, Klein R, Krauss JK, et al. Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas. Neurosurgery. 2011;68(4):1112\u20137.","journal-title":"Neurosurgery"},{"issue":"2","key":"2940_CR217","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MAO.0000000000000189","volume":"35","author":"CK Kandathil","year":"2014","unstructured":"Kandathil CK, Dilwali S, Wu CC, Ibrahimov M, McKenna MJ, Lee H, et al. Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo. Otol Neurotol. 2014;35(2):353\u20137.","journal-title":"Otol Neurotol"},{"issue":"9","key":"2940_CR218","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/MAO.0000000000001180","volume":"37","author":"CK Kandathil","year":"2016","unstructured":"Kandathil CK, Cunnane ME, McKenna MJ, Curtin HD, Stankovic KM. Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis. Otol Neurotol. 2016;37(9):1428\u201334.","journal-title":"Otol Neurotol"},{"issue":"9","key":"2940_CR219","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/lary.27114","volume":"128","author":"S MacKeith","year":"2018","unstructured":"MacKeith S, Wasson J, Baker C, Guilfoyle M, John D, Donnelly N, et al. Aspirin does not prevent growth of vestibular schwannomas: a case-control study. Laryngoscope. 2018;128(9):2139\u201344.","journal-title":"Laryngoscope"},{"issue":"1","key":"2940_CR220","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40478-019-0760-0","volume":"7","author":"F Behling","year":"2019","unstructured":"Behling F, Ries V, Skardelly M, Gepfner-Tuma I, Schuhmann M, Ebner FH, et al. COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake. Acta Neuropathol Commun. 2019;7(1):105.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2940_CR221","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1093\/neuros\/nyx516","volume":"82","author":"JJ Van Gompel","year":"2018","unstructured":"Van Gompel JJ, Agazzi S, Carlson ML, Adewumi DA, Hadjipanayis CG, Uhm JH, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on emerging therapies for the treatment of patients with vestibular schwannomas. Neurosurgery. 2018;82(2):E52\u20134.","journal-title":"Neurosurgery"},{"key":"2940_CR222","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.biopha.2017.08.085","volume":"95","author":"J Ma","year":"2017","unstructured":"Ma J, Cai Z, Wei H, Liu X, Zhao Q, Zhang T. The anti-tumor effect of aspirin: what we know and what we expect. Biomed Pharmacother. 2017;95:656\u201361.","journal-title":"Biomed Pharmacother"},{"key":"2940_CR223","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mito.2021.12.001","volume":"62","author":"H Akbari","year":"2022","unstructured":"Akbari H, Taghizadeh-Hesary F, Bahadori M. Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis. Mitochondrion. 2022;62:151\u20138.","journal-title":"Mitochondrion"},{"key":"2940_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/genes13101728","author":"F Taghizadeh-Hesary","year":"2022","unstructured":"Taghizadeh-Hesary F, Akbari H, Bahadori M, Behnam B. Targeted anti-mitochondrial therapy: the future of oncology. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13101728.","journal-title":"Genes"},{"key":"2940_CR225","doi-asserted-by":"publisher","DOI":"10.3171\/2019.7.JNS19879","author":"A Perry","year":"2019","unstructured":"Perry A, Graffeo CS, Carlstrom LP, Raghunathan A, Driscoll CLW, Neff BA, et al. Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma. J Neurosurg. 2019. https:\/\/doi.org\/10.3171\/2019.7.JNS19879.","journal-title":"J Neurosurg"},{"issue":"10","key":"2940_CR226","doi-asserted-by":"publisher","first-page":"319","DOI":"10.15698\/cst2019.10.201","volume":"3","author":"S Munir","year":"2019","unstructured":"Munir S, Lundsager MT, J\u00f8rgensen MA, Hansen M, Petersen TH, Bonefeld CM, et al. Inflammation induced PD-L1-specific T cells. Cell Stress. 2019;3(10):319\u201327.","journal-title":"Cell Stress"},{"issue":"1","key":"2940_CR227","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00262-020-02671-z","volume":"70","author":"JW Rutland","year":"2021","unstructured":"Rutland JW, Gill CM, Loewenstern J, Arib H, Pain M, Umphlett M, et al. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunol Immunother. 2021;70(1):169\u201376.","journal-title":"Cancer Immunol Immunother"},{"issue":"10045","key":"2940_CR228","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388(10045):661\u201372.","journal-title":"Lancet"},{"key":"2940_CR229","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072309","author":"S Delmaghani","year":"2020","unstructured":"Delmaghani S, El-Amraoui A. Inner ear gene therapies take off: current promises and future challenges. J of Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9072309.","journal-title":"J of Clin Med"},{"issue":"13","key":"2940_CR230","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1111\/jcmm.16610","volume":"25","author":"M Farhadi","year":"2021","unstructured":"Farhadi M, Razmara E, Balali M, Hajabbas Farshchi Y, Falah M. How Transmembrane Inner Ear (TMIE) plays role in the auditory system: a mystery to us. J Cell Mol Med. 2021;25(13):5869\u201383.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2940_CR231","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nbt.3801","volume":"35","author":"B Pan","year":"2017","unstructured":"Pan B, Askew C, Galvin A, Heman-Ackah S, Asai Y, Indzhykulian AA, et al. Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c. Nat Biotechnol. 2017;35(3):264\u201372.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"2940_CR232","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1073\/pnas.1817537116","volume":"116","author":"O Akil","year":"2019","unstructured":"Akil O, Dyka F, Calvet C, Emptoz A, Lahlou G, Nouaille S, et al. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci USA. 2019;116(10):4496\u2013501.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2940_CR233","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809396","author":"H Al-Moyed","year":"2019","unstructured":"Al-Moyed H, Cepeda AP, Jung S, Moser T, K\u00fcgler S, Reisinger E. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019. https:\/\/doi.org\/10.15252\/emmm.201809396.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2940_CR234","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73\u201380.","journal-title":"Nat Biotechnol"},{"issue":"7687","key":"2940_CR235","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature25164","volume":"553","author":"X Gao","year":"2018","unstructured":"Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. 2018;553(7687):217\u201321.","journal-title":"Nature"},{"issue":"1","key":"2940_CR236","doi-asserted-by":"publisher","first-page":"12922","DOI":"10.1038\/s41598-017-13032-9","volume":"7","author":"Y Ren","year":"2017","unstructured":"Ren Y, Sagers JE, Landegger LD, Bhatia SN, Stankovic KM. Tumor-penetrating delivery of siRNA against TNF\u03b1 to human vestibular schwannomas. Sci Rep. 2017;7(1):12922.","journal-title":"Sci Rep"},{"key":"2940_CR237","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.omtm.2022.06.012","volume":"26","author":"S Prabhakar","year":"2022","unstructured":"Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Haidar EA, Lule S, et al. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022;26:169\u201380.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"2940_CR238","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/hum.2012.094","volume":"24","author":"S Prabhakar","year":"2013","unstructured":"Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, et al. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther. 2013;24(2):152\u201362.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2940_CR239","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/neuonc\/noz065","volume":"21","author":"SG Ahmed","year":"2019","unstructured":"Ahmed SG, Abdelnabi A, Maguire CA, Doha M, Sagers JE, Lewis RM, et al. Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro Oncol. 2019;21(7):854\u201366.","journal-title":"Neuro Oncol"},{"key":"2940_CR240","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fncel.2019.00323","volume":"13","author":"Y Ren","year":"2019","unstructured":"Ren Y, Landegger LD, Stankovic KM. Gene therapy for human sensorineural hearing loss. Front Cell Neurosci. 2019;13:323.","journal-title":"Front Cell Neurosci"},{"key":"2940_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.10.026","author":"N Catasus","year":"2022","unstructured":"Catasus N, Rosas I, Bonache S, Negro A, Plana A, Salvador H, et al. Antisense oligonucleotides targeting exon 11 are able to partially rescue the Neurofibromatosis Type 2 phenotype in vitro. Mol Ther Nucleic Acids. 2022. https:\/\/doi.org\/10.1016\/j.omtn.2022.10.026.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2940_CR242","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000442514","volume":"21","author":"SK Plontke","year":"2016","unstructured":"Plontke SK, Hartsock JJ, Gill RM, Salt AN. Intracochlear drug injections through the round window membrane: measures to improve drug retention. Audiol Neurotol. 2016;21(2):72\u20139.","journal-title":"Audiol Neurotol"},{"issue":"1","key":"2940_CR243","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13619-022-00150-7","volume":"12","author":"J Duan","year":"2023","unstructured":"Duan J, Wang Y. Modeling nervous system tumors with human stem cells and organoids. Cell Regen. 2023;12(1):4.","journal-title":"Cell Regen"},{"issue":"3","key":"2940_CR244","first-page":"475","volume":"20","author":"G Hung","year":"2002","unstructured":"Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS, et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol. 2002;20(3):475\u201382.","journal-title":"Int J Oncol"},{"issue":"1","key":"2940_CR245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"24","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum Mol Genet. 2015;24(1):1\u20138.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2940_CR246","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc. 2019;14(2):541\u201355.","journal-title":"Nat Protoc"},{"issue":"11","key":"2940_CR247","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/01.mlg.0000240185.14224.7d","volume":"116","author":"LS Chang","year":"2006","unstructured":"Chang LS, Jacob A, Lorenz M, Rock J, Akhmametyeva EM, Mihai G, et al. Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. Laryngoscope. 2006;116(11):2018\u201326.","journal-title":"Laryngoscope"},{"issue":"5","key":"2940_CR248","first-page":"622","volume":"18","author":"KR Stidham","year":"1997","unstructured":"Stidham KR, Roberson JB Jr. Human vestibular schwannoma growth in the nude mouse: evaluation of a modified subcutaneous implantation model. Am J Otol. 1997;18(5):622\u20136.","journal-title":"Am J Otol"},{"issue":"4","key":"2940_CR249","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ng930","volume":"31","author":"C Fernandez-Valle","year":"2002","unstructured":"Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet. 2002;31(4):354\u201362.","journal-title":"Nat Genet"},{"issue":"2","key":"2940_CR250","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s004390050188","volume":"98","author":"DB Welling","year":"1996","unstructured":"Welling DB, Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, et al. Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet. 1996;98(2):189\u201393.","journal-title":"Hum Genet"},{"issue":"3","key":"2940_CR251","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MAO.0b013e318248ee02","volume":"33","author":"C Roosli","year":"2012","unstructured":"Roosli C, Linthicum FH Jr, Cureoglu S, Merchant SN. Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity. Otol Neurotol. 2012;33(3):473\u201380.","journal-title":"Otol Neurotol"},{"issue":"2","key":"2940_CR252","first-page":"312","volume":"17","author":"JB Nadol Jr","year":"1996","unstructured":"Nadol JB Jr, Diamond PF, Thornton AR. Correlation of hearing loss and radiologic dimensions of vestibular schwannomas (acoustic Neuromas). Am J Otol. 1996;17(2):312\u20136.","journal-title":"Am J Otol"},{"issue":"5","key":"2940_CR253","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/path.5908","volume":"257","author":"F Zhao","year":"2022","unstructured":"Zhao F, Chen Y, Li SW, Zhang J, Zhang S, Zhao XB, et al. Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma. J Pathol. 2022;257(5):620\u201334.","journal-title":"J Pathol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-02940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-023-02940-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-02940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T23:52:54Z","timestamp":1684799574000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-02940-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":253,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1186\/s12935-023-02940-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"28 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}